BO-653. Chugai.
BO-653 is an antioxidant under development by Chugai for the potential treatment of atherosclerosis and the prevention of restenosis. By November 2001, BO-653 was in phase II trials for restenosis in post-percutaneous transluminal coronary angioplasty in the US, and by April 2002, the compound was in phase I trials for the same indication in Japan.
AtheroGenics Inc, 8995 Westside Parkway, Alpharetta, GA 30004, USA. Cmeng@atherogenics.com
Charles Q
CQ
Meng
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy; D001572:Benzofurans / Q000494:pharmacology / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D023903:Coronary Restenosis / Q000517:prevention & control; D006801:Humans
C106512:2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran; D000975:Antioxidants; D001572:Benzofurans